BioDlink(TOT BIOPHARM) (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

BioDlink(TOT BIOPHARM)

Empowering Pharmaceutical Innovation, Improving Quality of Life, Safeguarding Human Health

Founded 2009 China

China 80 employees Series B Total: $108.00M Biopharma, Biotechnology +2

TOT BIOPHARM is a China-based startup that is dedicated to becoming the industry leading and trusted biopharmaceutical best partner for global clients. The company has extensive practical experience, mature technical platforms, and a robust quality system, which has enabled it to develop diversified strategic partnerships with domestic and international pharmaceutical companies. Their focus is to provide one-stop CDMO solutions for drug development and manufacturing, particularly in the field of biologics, including antibody-drug conjugates (ADCs). With a large-scale commercial GMP production base for biological drugs, TOT BIOPHARM has established itself as a key player in the industry, with a total manufacturing capacity exceeding 20,000 L. The company has also successfully built an integrated platform for ADCs, reducing transfer costs and regulatory risks. Moreover, they have a quality management system in line with commercial manufacturing, which has supported the commercial production of several marketed products. The last investment of $102.00M was in a Series B round on 08 August 2018, with participation from Chengwei Capital, Vivo Capital, Yuanta Financial Holdings Group, Cathay Capital, Center Ventures, 99Fund, GoldTech, and China Universal Asset Management. With a strong technological and commercial foundation, TOT BIOPHARM is well-positioned to continue its growth and impact within the biopharmaceutical industry.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	••••••	8	•••• ••••	08 Aug 2018
Series A	••••••	1		01 Jan 2010

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

••••••

•••• ••••

08 Aug 2018

Series A

••••••

01 Jan 2010

FAQ About BioDlink(TOT BIOPHARM)

Empowering Pharmaceutical Innovation, Improving Quality of Life, Safeguarding Human Health

BioDlink(TOT BIOPHARM) was founded in 2009.

BioDlink(TOT BIOPHARM) is headquartered in China.

BioDlink(TOT BIOPHARM) operates in the following industries: Biopharma, Biotechnology, Health Care, Pharmaceutical.

BioDlink(TOT BIOPHARM) has approximately 80 employees.

BioDlink(TOT BIOPHARM) has completed 2 funding rounds, raising a total of $108.00M. The latest funding stage is Series B.

Top alternatives and competitors to BioDlink(TOT BIOPHARM) include Byondis, ProJect Pharmaceutics GmbH, Shanghai Junshi Biosciences Co Ltd, CPC Scientific Inc., Cerbios-Pharma SA. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

BioDlink(TOT BIOPHARM) and Byondis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

BioDlink(TOT BIOPHARM)

General Information

Track BioDlink(TOT BIOPHARM)

Discover More

About BioDlink(TOT BIOPHARM)

Funding Rounds & Investors (2)

BioDlink(TOT BIOPHARM) Alternatives & Competitors

FAQ About BioDlink(TOT BIOPHARM)

Don't just browse. Track.